EVIDENCE LIBRARY

Can CBD Metabolism Produce a THC-Like Metabolite? What a 1993 Animal Study Found

A 1993 microsomal study identified a CBD-derived metabolite with THC-like effects in mice, but it did not establish meaningful formation or intoxication in humans.

Short answer: In a 1993 laboratory study, liver microsomes from guinea pigs, rats, and mice converted CBD through an epoxide intermediate to a metabolite described as 6β-hydroxymethyl-Δ9-THC. The isolated metabolite produced several THC-like effects when injected into mice. This was a mechanistic animal study, not proof that ordinary CBD use causes human intoxication.

What metabolic pathway was investigated?

The researchers examined oxidation at CBD’s 8,9-double bond. They identified 8R,9-epoxy-CBD by gas chromatography–mass spectrometry after incubation with hepatic microsomal fractions. Formation required NADPH and oxygen and was inhibited by compounds and conditions consistent with cytochrome P450 involvement.

The epoxide was then converted to two products: 8,9-dihydro-8,9-dihydroxy-CBD and 6β-hydroxymethyl-Δ9-THC. Formation differed among animal species and changed when epoxide hydrolase was inhibited.

How were the pharmacological effects tested?

The researchers injected the isolated THC-like metabolite intravenously into mice and measured catalepsy, analgesia, prolongation of pentobarbital sleep, and hypothermia. The metabolite produced effects in those assays, but they were less marked than the effects of Δ9-THC under the study conditions.

Why this does not establish a human CBD-to-THC conversion rate

The experiment combined isolated liver microsomes, enzyme inhibitors, purified metabolites, and intravenous mouse dosing. It did not measure how much of this metabolite forms after a typical human oral CBD dose, whether it reaches the brain at an active concentration, or whether it explains any real-world toxicology result.

Species differences are especially important because enzyme expression and competing metabolic pathways vary across guinea pigs, rats, mice, and humans.

What question can the study answer?

It supports a narrow proposition: CBD can undergo an oxidative pathway in animal microsomes that yields a structurally THC-related metabolite with measurable activity in mice. It cannot establish that a person who used a CBD product was impaired, that a THC-positive test arose from this pathway, or that the metabolite would be analytically indistinguishable from administered THC.

Source

Nagai K, et al. In vitro metabolic formation of a new metabolite, 6β-hydroxymethyl-Δ9-tetrahydrocannabinol, from cannabidiol through an epoxide intermediate and its pharmacological effects on mice. Biological & Pharmaceutical Bulletin. 1993;16(10):1008–1013. PubMed record (PMID 8287029).